Anticoagulant chitosan nanoparticles: synthesis, characterization and biological safety

doi:10.3969/j.issn.2095-4344.2015.47.020

Abstract

Abstract:

BACKGROUND: Studies have shown that chitosan and other natural polysaccharides have heparin-like anticoagulant function after sulfonated modification. Sulfonated chitosan has good anticoagulant property because the sulfonate group formed by sulfonated chitosan is similar with the active group of heparin.

OBJECTIVE: To prepare the anticoagulant chitosan nanoparticles and to detect its morphology, physical and chemical properties and biological security.

METHODS: Chitosan nanoparticles were synthesized by emulsion-chemical cross link. Sulfonated chitosan nanoparticles were synthesized by sulfonation reaction. Its morphology was described by transmission electron microscope. The peak-value change of its specific groups was observed by infrared spectroscopy. (1) Coagulation experiment: Heparin, chitosan nanoparticles and 10, 30 and 50 mg of sulfonated chitosan nanoparticles were added into the blood of Spraque-Dawley rats. The coagulation indicators were detected. (2) Hemolysis experiment: deionized water, physiological saline and 10, 30, 50 g/L sulfonated chitosan nanoparticles extracts were added into 2% red blood cell suspension of rabbits. The hemolysis rate was detected. (3) Cytotoxicity experiments: DMEM medium containing fetal bovine serum and 10, 30, 50 g/L sulfonated chitosan nanoparticle extracts were used to culture human umbilical vein endothelial cells. Cell relative growth rate and toxicity grading were detected after 72 hours.

RESULTS AND CONCLUSION: Scanning electron microscopy showed that sulfonated chitosan nanoparticles had good morphology, with a diameter of 50 nm. Infrared spectroscopy showed that the sulfonated replacement occurred. In vitro coagulation experiments showed that sulfonated chitosan nanoparticles had significant anticoagulant effects in a dose-dependent manner. Sulfonated chitosan nanoparticles meet the national safety standard for hemolysis rate of less than 5%, non-induced hemolysis property. Cytotoxicity assays showed that sulfonated chitosan nanoparticles extracts had no significant cytotoxicity, and its biological safety was in line with the national standards.
中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Key words: Chitosan, Nanostructures, Microspheres, Tissue Engineering

Wang Zi-jing, Liu Chao-yang, Qian Zhi-yong, Gao De-wei, Guo Xi-min. Anticoagulant chitosan nanoparticles: synthesis, characterization and biological safety[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(47): 7655-7659.

Figures/Tables 5

References

[1] Bilati U,Allemann E,Doelker E.Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles.Eur J Pharm Biopharm.2005;59(3):375-388.

[2] Huang G,Gao J,Hu ZB,et al.Controlled drug release from hydrogel nanoparticle networks.J Control Release.2004; 94(2-3):303-311.

[3] Bonian P,Petnova T,Manolova N,et al.pH-senstive hydrogels composed of chitosan and polyaerylamide: enzymatice degradation.J Bioact Compat Polym.2004;19:197-208.

[4] Chang KL,Tai MC,Cheng EH.Kinetics and products of the degradation of chitosan by hydrogen peroxide.J Agric Food Chem.2001;49(10):4845-4851.

[5] Vanfrvord PJ,Matthw HW,Desilva SP,et al.Evaluation of the biocompatibility of a chitosan scaffold in mice.J Biomed Mater Res.2002;59(3):585-590.

[6] Rao SB,Shama CP.Use of chitosan as a biomaterial: studies on its safety and hemostatic potential.J Biomed Mater Res. 1997;34(1):21.

[7] Chou TC,Li CY,Lee AR,et al.Mechanism of inhibition of platelet aggregation by HCL-31D.Eur J Pharmacol.2000; 387(2):125-131.

[8] 尹刚,侯春林.浅析壳聚糖的止血作用及机理[J].生物骨科材料与临床研究,2009,6(4):18-23.

[9] Dodane V,Khan AM,Merwin JR.Efect of chitosan on epithelia permeability and structure.Int J Pharm.1999; 182(1):21-32.

[10] 王琰,李正荣,潘飞燕,等.纳米脂质体包裹胰岛素经Caco-2细胞转运的研究[J].中国药理学通报,2005,21(1):78-81.

[11] Fernandez UR,Calvo P,Remunan LC,et al.Enhancement of nasal absorption of insulin using chitosan nanoparticles.Pharm Res.1999;16(10):1576-1580.

[12] Mitra S,Caur U,Ghosh PC,et al.Tumor targeted delivery of encapsulated dextran -doxorubicin conjugate using chitosan nanoparticles as carrier.J Control Release. 2001;74(1-3): 317-323.

[13] 王斌.壳聚糖的硫酸/氯磺酸酯化[D].成都:西南石油大学,2004.

[14] 杨越冬.磺化6-羧基壳聚糖的制备、表征及血液相容性研究[D].天津:天津大学,2007.

[15] 蒋挺大.甲壳素[M].北京:化学工业出版社,2003:128.

[16] Amiji MM.Platelet adhesion and activation on an amphoteric chitosan derivative bearing sulfonate groups.Colloids Surf B Biointerfaces.1998;10(5):263-271.

[17] 罗华丽,臧剑甬,张秀娟.壳聚糖载药微球的制备和体外释放研究[J].河南科学,2011,29(1):20-24.

[18] 王世敏,许祖勋,傅晶.纳米材料制备技术[M].北京:化学工业出版社,2002:1-6.

[19] 许加超,肖英龙.壳聚糖硫酸醋在药物中的应用[J].海洋科学, 1996, 20(2):2-4.

[20] Baumann H,Faust V.Concepts for improved regioselective placement of O-sulfo, N-sulo, N-acetyl and N-carboxymethyl groups in chitosan derivatives.Carbohydrate Res. 2001; 331(1):43-44.

[21] 王声宇,张文清.壳聚糖硫酸酯的合成及其抑菌作用[J].功能高分子学报,2007,19(4): 440-442.

[22] 张虹.壳聚糖的改性及其抗凝血活性研究[D].安徽:安徽工程大学,2014.